A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities



Status:Recruiting
Conditions:Cancer, Women's Studies
Therapuetic Areas:Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:8/16/2018
Start Date:April 6, 2018
End Date:September 2021
Contact:Mark Kirshbaum, MD
Email:MKirschbaum@taihooncology.com
Phone:609-750-5300

Use our guide to learn which trials are right for you!

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities

This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to
evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This
study consists of Phase 1 and Phase 2a components in subjects with advanced solid tumors with
HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard
therapy or for which no standard therapy exists, particularly urothelial cancer, biliary
tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.


Inclusion Criteria:

1. Male or females with an age ≥ 18 years.

2. Subjects with histological- or cytological-confirmed, advanced cancer, who have
progressed on (or not been able to tolerate) standard therapy or for whom no standard
anticancer therapy exists

1. For Phase 1, only subjects HER2 or HER3 molecular/genetic alterations will be
enrolled.

2. For Phase 2a, subjects with one of the following tumor types will be enrolled:

i. Urothelial cancer with HER2 or HER3 mutation ii. Biliary tract cancer with HER2 or
HER3 mutation iii. Breast cancer with HER2 or HER3 mutation iv. Breast cancer with
HER2 amplification or overexpression v. NSCLC with HER2 or HER3 mutation vi. CRC with
HER2 mutation or amplification vii. Other tumors with HER2
mutation/amplification/overexpression or HER3 mutation (gastric/GEJ, endometrial).

3. At least 1 measurable lesion for solid tumor

4. Is able to take medications orally (e.g., no feeding tube).

5. Able to agree to and sign informed consent and to comply with the protocol

6. Has adequate organ function

Exclusion Criteria:

1. Has a serious illness or medical condition(s)

2. Has received treatment with any proscribed treatments within specified time frames
prior to study drug administration

3. Impaired cardiac function or clinically significant cardiac disease
We found this trial at
6
sites
114 Rue Edouard Vaillant
Paris, 94800
Phone: +33 142 114 385
?
mi
from
Paris,
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Phone: 626-256-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Phone: 404-778-5378
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-563-1055
?
mi
from
Houston, TX
Click here to add this to my saved trials
Nashville, Tennessee 37203
Phone: 615-524-4461
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Phone: 516-470-6901
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials